LT
VRTX icon

Legacy Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
+432
New +$191K 0.04% 198

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Legacy Trust's VRTX Position: Q2 2026 in Review

Legacy Trust opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 432 shares worth $215K. The stake represents 0.04% of the portfolio and ranks #198 among its holdings.

1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Legacy Trust held 432 shares of Vertex Pharmaceuticals worth $215K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Legacy Trust position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.04% of Legacy Trust's portfolio in Q2 2026, its #198 holding.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Legacy Trust's 13F filing for Q2 2026, filed 31 Jul 2026.